Results 101 to 110 of about 31,195 (193)

The Mechanism of Tigecycline Resistance in Acinetobacter baumannii under Sub-Minimal Inhibitory Concentrations of Tigecycline

open access: yes
The presence of sub-minimal inhibitory concentration (sub-MIC) antibiotics in our environment is widespread, and their ability to induce antibiotic resistance is inevitable.
Cunwei Liu   +4 more
core   +1 more source

A promising metabolite, 9-aminominocycline, restores the sensitivity of tigecycline against tet(X4)-positive Escherichia coli

open access: yesFrontiers in Microbiology
The emergence and widespread of tigecycline resistance undoubtedly poses a serious threat to public health globally. The exploration of combination therapies has become preferred antibacterial strategies to alleviate this global burden.
Feifei Sun   +6 more
doaj   +1 more source

Salvage Use of Tigecycline for Severely Ill Children

open access: yes, 2018
Objective: Tigecycline has a wide spectrum antimicrobial activity including multi-drug resistant and extended drug resistant nosocomial Gram-negative bacteria. Although its pediatric use has not been approved, clinicians are sometimes obligated to choose
Akturk, Hacer   +9 more
core   +1 more source

Cerebrospinal fluid penetration of tigecycline

open access: yes, 2014
Today very little is known about tigecycline penetration into cerebrospinal fluid (CSF). We report, in a clinical setting, tigecycline concentration, and the area under concentration-time curve (AUC) - both in blood and in CSF - of a patient affected by
Carlo Pallotto   +6 more
core  

Resistance to tigecycline increased in a stepwise manner (as a fold increase over the MIC of K. pneumoniae XH209) following serial passage in tigecycline.

open access: yes, 2016
Resistance to tigecycline increased in a stepwise manner (as a fold increase over the MIC of K. pneumoniae XH209) following serial passage in tigecycline.
Qiong Chen (327492)   +8 more
core   +1 more source

EUCAST Technical Note on tigecycline

open access: yes, 2006
Tigecycline is an injectable antibacterial agent derived from the tetracyclines and classified by the manufacturer as a glycylcycline. Tigecycline was registered by the European Medicines Agency (EMEA) in May 2006 for parenteral use in complicated ...
HRYNIEWICZ W.   +10 more
core   +1 more source

AdeABC-mediated efflux and tigecycline MICs for epidemic clones of Acinetobacter baumannii

open access: yes, 2010
Objectives Tigecycline non-susceptibility in individual Acinetobacter baumannii isolates has been associated with up-regulation of the resistance–nodulation–division (RND)-type efflux system, AdeABC.
Thomas, Claire P.   +19 more
core   +1 more source

Tigecycline in carbapenem-resistant Acinetobacter baumannii bacteraemia: Susceptibility and clinical outcome

open access: yes, 2013
Although tigecycline is considered one of the few therapeutic options for carbapenem-resistant Acinetobacter baumannii (CRAB) bacteraemia, its role in the treatment of CRAB bacteraemia remains unclear.
Kim, Eu Suk   +9 more
core   +1 more source

In Vitro Activity Of Tigecycline Against Brucella Spp.

open access: yes, 2009
Objectives: There are no published data regarding efficacy of tigecycline in brucellosis and in vitro data are scarce. We compared the in vitro activity of tigecycline to that of trimethoprim-sulfamethoxazole, rifampicin, tetracycline, streptomycin and ...
Gur, Deniz   +2 more
core  

Home - About - Disclaimer - Privacy